Transfusion-related inhibition of cytokines (TRICK). Experimental transfer of neutralizing autoantibodies to interleukin-6 by plasma transfusions

Vox Sanguinis

Volumn 92, Issue 3, 2007, Pages 213-223

  Hansen, M B ^a   Galle, P ^a   Salomo, M ^a   Svenson, M ^a   Dickmeiss, E ^a   Gimsing, P ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Blood transfusion; Cytokine autoantibodies; IL 6 deficiency; Immune modulation; IVIg; Plasma

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MELPHALAN; NEUTRALIZING ANTIBODY; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLEEDING; BLOOD TRANSFUSION REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CAUSE OF DEATH; CONCENTRATION (PARAMETERS); DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMA TRANSFUSION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSFUSION RELATED INHIBITION OF CYTOKINES; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODY AFFINITY; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; BLOOD COMPONENT TRANSFUSION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA;

EID: 33847679967     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00881.x     Document Type: Article

References (51)

1. Moyner K, Michaelsen TE: IgG subclass distribution among antibodies to varicella-zoster virus in human varicella/zoster immunoglobulin preparations and the corresponding donor plasma. J Biol Stand 1988; 16:157-164
2. Johansson SG, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, Soderstrom L, Stiller V, Oman H: Passive IgE-sensitization by blood transfusion. Allergy 2005; 60:1192-1199
3. Sapatnekar S, Sharma G, Downes KA, Wiersma S, McGrath C, Yomtovian R: Acute hemolytic transfusion reaction in a pediatric patient following transfusion of apheresis platelets. J Clin Apher 2005; 20:225-229
4. Oren H, Duman N, Anal O, Ozkan H, Irken G: Detection and clinical evaluation of antineutrophil antibodies in neonates who had a blood transfusion or exchange transfusion. Pediatr Int 2005; 47:518-522
5. Ballem PJ, Buskard NA, Decary F, Doubroff P: Post-transfusion purpura secondary to passive transfer of anti-P1A1 by blood transfusion. Br J Haematol 1987; 66:113-114
6. Morishita K, Wakamoto S, Miyazaki T, Sato S, Fujihara M, Kaneko S, Yasuda H, Yamamoto S, Azuma H, Kato T, Ikeda H: Life-threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti-CD36 (Nak) isoantibody. Transfusion 2005; 45:803-806
7. Warkentin TE, Smith JW, Hayward CP, Ali AM, Kelton JG: Thrombocytopenia caused by passive transfusion of antiglycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood 1992; 79:2480-2484
8. Hansen MB. Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. APMIS Suppl 1996; 59:1-33
9. Bendtzen K, Hansen MB, Diamant M, Ross C, Svenson M: Naturally occurring autoantibodies to interleukin-1 alpha, interleukin-6, interleukin-10, and interferon-alpha. J Interferon Res 1994; 14:157-158
10. Galle P, Svenson M, Bendtzen K, Hansen MB: High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 2004; 34:3267-3275
11. Hansen MB, Svenson M, Bendtzen K: Human anti-interleukin 1 alpha antibodies. Immunol Lett 1991; 30:133-139
12. Hansen MB, Svenson M, Diamant M, Bendtzen K: Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 1991; 33:777-781
13. Hansen MB, Svenson M, Diamant M, Bendtzen K: High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993; 5:72-80
14. Hansen MB, Svenson M, Abell K, Varming K, Nielsen HP, Bertelsen A, Bendtzen K: Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. Eur J Clin Invest 1994; 24:212-218
15. Menetrier-Caux C, Briere F, Jouvenne P, Peyron E, Peyron F, Banchereau J: Identification of human IgG autoantibodies specific for IL-10. Clin Exp Immunol 1996; 104:173-179
16. Ross C, Svenson M, Hansen MB, Veijsgaard GL, Bendtzen K: Specific autoantibodies directed against interferon-alpha in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994; 14:159-160
17. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995; 95:1974-1978
18. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K: Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. Blood 1997; 90:2376-2380
19. Svenson M, Hansen MB, Bendtzen K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92:2533-2539
20. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K: Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91:2054-2061
21. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ: Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481-486
22. Lin FC, Chang GD, Chern MS, Chen YC, Chang SC: Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006; 61:528-534
23. Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS: Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95:85-92
24. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF, Oh-Eda M, Ishige I, Eishi Y, Kitamura T, Yamada Y, Hanaoka K, Keicho N: High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103:1089-1098
25. Hoflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, Docke WD, Grutz G, Meisel C, Halle E, Gobel UB, Volk HD, Suttorp N: Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004; 103:673-675
26. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, Nicol M, Scholvinck E, Relman D, Waddell S, Langford P, Sheehan B, Semple L, Wilkinson KA, Wilkinson RJ, Ress S, Hibberd M, Levin M: Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 2005; 115:2480-2488
27. Ciapponi L, Maione D, Scoumanne A, Costa P, Hansen MB, Svenson M, Bendtzen K, Alonzi T, Paonessa G, Cortese R, Ciliberto G, Savino R: Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol 1997; 15:997-1001
28. Galle P, Hougs L, Barington T, Svenson M, Svejgaard A, Thomsen AR, Bendtzen K, Hansen MB: Knocking out IL-6 by vaccination. Eur J Immunol 2004; 34:291-300
29. Hansen MB, Svenson M, Abell K, Yasukawa K, Diamant M, Bendtzen K: Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 1995; 25:348-354
30. Hansen MB, Svenson M, Diamant M, Abell K, Bendtzen K: Interleukin-6 autoantibodies: possible biological and clinical significance. Leukemia 1995; 9:1113-1115
31. Kopf M, Ramsay A, Brombacher F, Baumann H, Freer G, Galanos C, Gutierrez-Ramos JC, Kohler G: Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann N Y Acad Sci 1995; 762:308-318
32. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8:75-79
33. Hansen MB, Svenson M, Diamant M, Ross C, Bendtzen K: Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. Blood 1995; 85:1145
34. Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9:4653-4665
35. Mahtouk K, De Jourdan MVJ, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B: An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004; 103:1829-1837
36. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842-854
37. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685-691
38. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B: High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992; 22:2819-2824
39. Gomez CR, Goral J, Ramirez L, Kopf M, Kovacs EJ: Aberrant acute-phase response in aged interleukin-6 knockout mice. Shock 2006; 25:581-585
40. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-342
41. Kopf M, Herren S, Wiles MV, Pepys MB, Kosco-Vilbois MH: Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998; 188:1895-1906
42. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH: Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997; 65:4843-4849
43. Homann C, Hansen MB, Graudal N, Hasselqvist P, Svenson M, Bendtzen K, Thomsen AC, Garred P: Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand J Immunol 1996; 44:623-629
44. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief report. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330:602-605
45. Montero-Julian FA, Gautherot E, Wijdenes J, Klein B, Brailly H: Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies. enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies. J Interferon Res 1994; 14:301-302
46. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755
47. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-19
48. Sacher RA: Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001; 108:S139-S146
49. Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC: Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1994; 1:725-731
50. Paul R, Koedel U, Winkler F, Kieseier BC, Fontana A, Kopf M, Hartung HP, Pfister HW: Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain 2003:126(Pt 8):1873-1882
51. van der PT, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF: Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176:439-444